These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16163638)

  • 1. HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.
    Campa A; Yang Z; Lai S; Xue L; Phillips JC; Sales S; Page JB; Baum MK
    Clin Infect Dis; 2005 Oct; 41(8):1179-85. PubMed ID: 16163638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003.
    Tang AM; Jacobson DL; Spiegelman D; Knox TA; Wanke C
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):70-6. PubMed ID: 16123685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Wanke CA; Silva M; Knox TA; Forrester J; Speigelman D; Gorbach SL
    Clin Infect Dis; 2000 Sep; 31(3):803-5. PubMed ID: 11017833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Viremia and Wasting Before Antiretroviral Therapy Are Associated With Pneumonia in Early-Treated HIV-Infected Kenyan Infants.
    Sridharan G; Wamalwa D; John-Stewart G; Tapia K; Langat A; Moraa Okinyi H; Adhiambo J; Chebet D; Maleche-Obimbo E; Karr CJ; Benki-Nugent S
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):245-252. PubMed ID: 27481854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort.
    Mangili A; Murman DH; Zampini AM; Wanke CA
    Clin Infect Dis; 2006 Mar; 42(6):836-42. PubMed ID: 16477562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.
    Baum MK; Rafie C; Lai S; Sales S; Page B; Campa A
    J Acquir Immune Defic Syndr; 2009 Jan; 50(1):93-9. PubMed ID: 19295339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy.
    Welch K; Morse A;
    AIDS Patient Care STDS; 2002 Feb; 16(2):75-81. PubMed ID: 11874639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV treatment in drug abusers: impact of alcohol use.
    Miguez MJ; Shor-Posner G; Morales G; Rodriguez A; Burbano X
    Addict Biol; 2003 Mar; 8(1):33-7. PubMed ID: 12745413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy.
    Tang AM; Forrester J; Spiegelman D; Knox TA; Tchetgen E; Gorbach SL
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):230-6. PubMed ID: 12394802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
    Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
    Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
    Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in body cell mass and decrease in wasting are associated with increasing potency of antiretroviral therapy for HIV infection.
    Ferrando SJ; Rabkin JG; Lin SH; McElhiney M
    AIDS Patient Care STDS; 2005 Apr; 19(4):216-23. PubMed ID: 15857193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy.
    Batterham MJ; Garsia R; Greenop P
    Int J STD AIDS; 2002 Nov; 13(11):744-7. PubMed ID: 12437893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment.
    Palepu A; Horton NJ; Tibbetts N; Meli S; Samet JH
    Addiction; 2004 Mar; 99(3):361-8. PubMed ID: 14982549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?
    Shikuma CM; Valcour VG; Ratto-Kim S; Williams AE; Souza S; Gerschenson M; Day L; Kim JH; Shiramizu B
    Clin Infect Dis; 2005 Jun; 40(12):1846-8. PubMed ID: 15909275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.